<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573960</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-M091-507</org_study_id>
    <nct_id>NCT03573960</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer</brief_title>
  <official_title>Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Pharmaceuticals India Pvt. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of lenvatinib in participants with&#xD;
      recurrent, metastatic radio-iodine refractory differentiated thyroid cancer (DTC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">March 20, 2021</completion_date>
  <primary_completion_date type="Actual">March 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>TEAEs are defined as undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment. Adverse events (AEs) will be graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Here grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activity of daily living (ADL), grade 4: Life-threatening consequences; urgent intervention indicated and grade 5: Death related to AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Dose Reductions</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>The number of instances of participants having to reduce the dosage of study drug based on specified toxicities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to First Dose Reduction</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Time to first dose reduction was calculated as the time period from the first dose to the first dose reduction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Week 24</time_frame>
    <description>ORR at 24 weeks is defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR). CR is defined as disappearance of all target and non-target lesions. All lymph nodes must be non-pathological in size (less than [&lt;] 10 millimeter [mm] short axis). PR is defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From date of first dose of study drug until documentation of disease progression or death from any cause (whichever occurs first) or up to approximately Week 24</time_frame>
    <description>PFS is defined as the time from enrollment of participant in to study to the first sign of Progressive Disease (PD) or death due to any cause if the participant dies without experiencing PD. Disease progression per response evaluation criteria in solid tumor (RECIST) v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Greater Than or Equal to (&gt;=) Grade 2 Other TEAEs</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>TEAEs are defined as undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment. The severity of all AEs will be graded according to CTCAE where grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL, grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL, grade 4: Life-threatening consequences; urgent intervention indicated and grade 5: Death related to AE.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Thyroid Neoplasms</condition>
  <arm_group>
    <arm_group_label>Lenvatinib 24 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily with or without food in 28-day cycles until disease progression or until unacceptable toxicity occurs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib capsules.</description>
    <arm_group_label>Lenvatinib 24 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females who are diagnosed with locally Recurrent or Metastatic, Progressive,&#xD;
             Radioiodine Refractory DTC, Lenvatinib naive and able to provide written informed&#xD;
             consent.&#xD;
&#xD;
          2. Histologically or cytologically confirmed diagnosis of one of the following DTC&#xD;
             subtypes: Papillary thyroid cancer (PTC) (including the follicular variants and other&#xD;
             variants), Follicular thyroid cancer (FTC) (including Hurthle cell, Clear cell and&#xD;
             Insular subtypes).&#xD;
&#xD;
          3. Measurable disease meeting the following criteria: i) At least 1 lesion &gt;= 1.0&#xD;
             centimeter (cm) in the longest diameter for a non-lymph node or &gt;= 1.5 cm in the&#xD;
             short-axis diameter for a lymph node which is serially measurable according to RECIST&#xD;
             1.1 using computerized tomography/magnetic resonance imaging (CT/MRI). ii) Lesions&#xD;
             that have had external beam radiotherapy (EBRT) or locoregional therapies such as&#xD;
             radiofrequency (RF) ablation must have shown evidence of PD based on RECIST 1.1 to be&#xD;
             deemed a target lesion.&#xD;
&#xD;
          4. Evidence of disease progression within 12 months of screening scan.&#xD;
&#xD;
          5. Require thyroxine suppression therapy and thyroid stimulating hormone (TSH) should not&#xD;
             be elevated (TSH should be less than [&lt;] 4.0 milli-international units per liter&#xD;
             [mIU/L]).&#xD;
&#xD;
          6. Participant must be radioiodine-refractory or resistant within 12 months of&#xD;
             radioiodine therapy and have one of the following:&#xD;
&#xD;
               -  One or more measurable lesions that do not demonstrate iodine uptake on any&#xD;
                  radioiodine scan.&#xD;
&#xD;
               -  One or more measurable lesions that have substantially increased in size within&#xD;
                  12 months of radioiodine therapy, despite demonstration of radioiodine activity&#xD;
                  at the time of that treatment by pre- or post-treatment scanning.&#xD;
&#xD;
               -  Cumulative activity of radioiodine of greater than (&gt;) 600 milliecurie (mCi) or&#xD;
                  22 gigabecquerels (GBq), with the last dose administered at least 6 months prior&#xD;
                  to study entry.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          8. Based on following laboratory assessment:&#xD;
&#xD;
               -  Creatinine clearance &gt;= 30 milliliter per minute (mL/min) according to the&#xD;
                  Cockcroft and Gault formula.&#xD;
&#xD;
               -  Adequate blood coagulation function as evidenced by an International Normalized&#xD;
                  Ratio (INR) less than or equal to (&lt;=) 1.5.&#xD;
&#xD;
               -  Adequate bone marrow function:&#xD;
&#xD;
                  i. Absolute neutrophil count (ANC) &gt;=1.5*10^9/liter (L) ii. Hemoglobin &gt;= 9.0&#xD;
                  gram per deciliter (g/dL) (can be corrected by growth factor or transfusion) iii.&#xD;
                  Platelet count &gt;=100 * 10^9/L&#xD;
&#xD;
               -  Adequate liver function:&#xD;
&#xD;
                  i. Bilirubin &lt;= 1.5*upper limit of normal (ULN) except for unconjugated&#xD;
                  hyperbilirubinemia or Gilbert's syndrome.&#xD;
&#xD;
             ii. Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate&#xD;
             aminotransferase (AST) &lt;= 3*ULN (&lt;= 5*ULN if participant has liver metastases). If ALP&#xD;
             is &gt; 3*ULN (in the absence of liver metastases) or &gt; 5*ULN (in the presence of liver&#xD;
             metastases) and participants are also known to have bone metastases, the&#xD;
             liver-specific ALP must be separated from the total and used to assess the liver&#xD;
             function instead of the total ALP.&#xD;
&#xD;
          9. Urine dipstick proteinuria should be &lt; 2+. If &gt; or equal 2 gram (g) proteinuria is&#xD;
             detected with dipstick, a 24-hour period urine test will be performed and the result&#xD;
             should be &lt; or equal to 1 g/24 hours to permit the inclusion of the patient in the&#xD;
             clinical trial.&#xD;
&#xD;
         10. Females of childbearing potential must not have had unprotected sexual intercourse&#xD;
             within 30 days before program entry and must agree to use a highly effective method of&#xD;
             contraception (example, total abstinence, an intrauterine device, a double-barrier&#xD;
             method (such as condom plus diaphragm with spermicide), a contraceptive implant, an&#xD;
             oral contraceptive, or have a vasectomized partner with confirmed azoospermia)&#xD;
             throughout the entire program.&#xD;
&#xD;
               -  If currently abstinent, participants must agree to use a double-barrier method as&#xD;
                  described above if they become sexually active during the study period or for 30&#xD;
                  days after study drug discontinuation.&#xD;
&#xD;
               -  Females who are using hormonal contraceptives must have been on a stable dose of&#xD;
                  the same hormonal contraceptive product for at least 4 weeks before dosing and&#xD;
                  must continue to use the same contraceptive during the study and for 30 days&#xD;
                  after study drug discontinuation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anaplastic or medullary carcinoma of the thyroid.&#xD;
&#xD;
          2. Two or more prior vascular endothelial growth factor (VEGF)/vascular endothelial&#xD;
             growth factor receptor (VEGFR)-targeted therapies or any ongoing treatment for&#xD;
             iodine-131 (131I) refractory DTC other than TSH-suppressive thyroid hormone therapy.&#xD;
&#xD;
          3. Blood pressure (BP) &gt;= 140 millimeter of mercury (mmHg) Systolic and &gt;= 90 mmHg&#xD;
             Diastolic at screening with or without antihypertensive medications.&#xD;
&#xD;
          4. Woman who are lactating or pregnant at screening or baseline.&#xD;
&#xD;
          5. Participants who received any anticancer treatment within 21 days or any&#xD;
             investigational agent within 30 days prior to the first dose of study drug. (This does&#xD;
             not apply to the use of TSH-suppressive thyroid hormone therapy).&#xD;
&#xD;
          6. Gastrointestinal malabsorption or any other condition that in the opinion of the&#xD;
             investigator affected the absorption of Lenvatinib.&#xD;
&#xD;
          7. Participant has history of congestive heart failure with New York Heart Association&#xD;
             (NYHA) Classification &gt; II, unstable angina, myocardial infarction, serious cardiac&#xD;
             arrhythmia, or stroke within the past 6 months.&#xD;
&#xD;
          8. Electrocardiogram (ECG) with QT interval (QTc) interval &gt;= 450 millisecond (msec).&#xD;
             (According to Bazett's formula).&#xD;
&#xD;
          9. Bleeding or thrombotic disorders or use of anticoagulants, such as warfarin, or&#xD;
             similar agents requiring therapeutic international normalized ration (INR) monitoring.&#xD;
             (Treatment with low molecular weight heparin [LMWH] will be allowed).&#xD;
&#xD;
         10. Existing anti-cancer therapy-related toxicities of CTCAE version 4.03 grade &gt;= 2,&#xD;
             except alopecia and infertility.&#xD;
&#xD;
         11. Any history of or concomitant medical condition that, in the opinion of the&#xD;
             investigator, would compromise participant's ability to safely complete the protocol.&#xD;
&#xD;
         12. Active infection (any infection requiring treatment).&#xD;
&#xD;
         13. Active malignancy (except for differentiated thyroid carcinoma, or definitively&#xD;
             treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma&#xD;
             in-situ of the cervix) within the past 24 months.&#xD;
&#xD;
         14. Epistaxis or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3&#xD;
             weeks prior to the first dose of study drug.&#xD;
&#xD;
         15. Known intolerance to Lenvatinib (or any of the excipients).&#xD;
&#xD;
         16. Participants with clinically significant laboratory investigations as per the&#xD;
             investigator's judgment.&#xD;
&#xD;
         17. Participation in any interventional clinical study within the past 90 days of&#xD;
             enrollment to treatment.&#xD;
&#xD;
         18. Male or female of childbearing potential, unwilling to use adequate methods of&#xD;
             contraception throughout the study.&#xD;
&#xD;
         19. Participants whom had major surgery within 3 weeks prior to study entry, or who have&#xD;
             not recovered from prior major surgery, or whom have surgery scheduled during the&#xD;
             course of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indraprastha Apollo Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shetty's Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>Bhubaneshwar</city>
        <state>Odisa</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. P. Medical College &amp; A. G. Hospitals</name>
      <address>
        <city>BÄ«kaner</city>
        <state>Rajasthan</state>
        <zip>334003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BL Kapoor Hospital, New Delhi</name>
      <address>
        <city>New Delhi</city>
        <zip>110005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indrayani Hospital, Alandi</name>
      <address>
        <city>Pune</city>
        <zip>412105</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Cancer Centre</name>
      <address>
        <city>Vijayawada</city>
        <zip>520002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lenvatinib, E7080, Refractory Differentiated Thyroid Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

